Hospital

Studies support the use of a COVID-19 vaccine booster dose to increase protection among immunocompromised individuals.

These materials are present in some angiotensin II receptor blockers used to treat heart failure and high blood pressure, and they have the potential to cause cancer.

Multiple GBS vaccine candidates are in development, but none are available despite development efforts spanning multiple decades.

Ibrutinib in combination with venetoclax shows promise in patients with previously untreated chronic lymphocytic leukemia.

Febrile seizures occur in young, healthy children with normal development.

Further, among premenopausal women, those who received chemotherapy had a 40% relative improvement in IDFS compared to those administered endocrine therapy alone.

Affordability in drug pricing can be addressed by bringing the manufacturer and plan sponsor to negotiate costs and determine fair compensation for product and service providers in the supply chain.

Experts from the Infectious Diseases Society of America recommend enhanced protection measures against the Omicron COVID-19 variant.

The combination of daratumumab with hyaluronidase (Darzalex Faspro), hyaluronidase-fihj, carfilzomib (Kyprolis), and dexamethasone is indicated for the treatment of adult patients with relapsed/refractory multiple myeloma who have received 1 to 3 prior lines of therapy.

The diagnostic tool widens the age group of individuals who can get tested and can be used in conjunction with a mammogram.

The researchers said these results reinforce the importance of a third booster dose of the vaccine.

Stem cell therapy was associated with a reduction of the number of heart attacks, strokes, and death among people with chronic, high-risk, NYHA class 2 or 3 heart failure with reduced ejection fraction (HFrEF), according to a study presented at the American Heart Association’s Scientific Sessions 2021.

The data included more than 21,500 children and adolescents 17 years of age and younger with HIV and more than 255,000 adults with HIV, all of whom began receiving ART between 2010 and 2019.

Study results also show that the probability of dying from any cause is also 40% higher for individuals who have cardiovascular disease.

Study results show more activity in brain areas affecting sympathy and movement when the women viewed the photos.

The long-term implications of post-COVID-19 myocardial injury detected by cardiac MRI are still unknown.

Debra Goff, PharmD, FIDSA, FCCP, infectious diseases specialist at the Ohio State University Wexner Medical Center, discusses Clostridioides difficile awareness and potential future treatments.

Olaparib was the first PARP inhibitor to be developed and has been the most studied.

Obesity, high blood pressure, and diabetes were the most common comorbidities.

The best protection against all variants of COVID-19 continues to be vaccination, including a booster shot for eligible individuals.

These benefits included increased survival, a lower risk of hospital readmission for heart failure, and an overall improvement in quality of life.

The investigators note that this is the largest annual decrease in 2 decades of reporting.

Approximately half of people with HCV don't know they're infected, mainly because they have no symptoms.

Officials with the FDA have approved the QuantiFERON-TB Gold Plus assay for use on DiaSorin’s automated LIAISON XS platform.

Investigators have developed an antibody-based treatment for Alzheimer disease, as well as a protein-based vaccine.

Further, at daily doses of at least 100 mg, the rates of VTE with milvexian were significantly lower than with enoxaparin, according to the study authors.

The team found that out of more than 18,751 live births, 1008 cancer diagnoses were made in offspring 0 to 58 years of age.

Although specialty therapies have the potential to help people live healthier lives, their cost and complexity can create distinct challenges.